已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Treatment of Neuromyelitis Optica

作者
Kazuo Fujihara
出处
期刊:Nihon Rinshō Men'eki Gakkai kaishi [Japanese Society for Clinical Immunology]
卷期号:35 (2): 129-135 被引量:5
标识
DOI:10.2177/jsci.35.129
摘要

Neuromyelitis optica (NMO) or Devic's disease is an inflammatory neurologic disease characterized by severe optic neuritis and transverse myelitis. Other features of NMO include female preponderance, higher onset age, severe functional disability, longitudinally extensive spinal cord lesions (longer than 3 vertebral segments), and oligoclonal IgG bands negativity. Brain lesions are not uncommon in NMO. The relation between NMO and multiple sclerosis (MS) has long been a matter of controversy, but since the discovery of anti-aquaporin 4 (AQP4) antibody (NMO-IgG), an NMO-specific autoantibody, the clinical, MRI, and laboratory features that distinguish NMO from MS have been clarified. Anti-AQP4 antibody binds to the extracellular domain of AQP4, which is highly expressed in endfeet of astrocytes. Recent neuropathological studies, analysis of CSF-GFAP levels during relapse and experimental studies strongly suggest that NMO is an anti-AQP4 antibody-mediated astrocytopathic disease and that T cell-mediated CNS inflammation is necessary to develop NMO. Also, IL-6 is remarkably elevated in the CSF and appears to regulate plasmablasts to produce anti-AQP4 antibody. Therefore, from the therapeutic point of view, depletion of anti-AQP4 antibody, suppression of T cell response to trigger relapse and anti-IL-6 therapy seem to be pivotal. High-dose intravenous methylprednisolone is the first-line therapy for acute exacerbations of NMO. But plasma exchange should be started soon if corticosteroid is not efficacious. If untreated, AQP4 antibody-positive patients are highly likely to experience relapses within a year. Thus, immunosuppressive therapy (corticosteroids, immunosuppressants, rituximab) should be initiated without delay. Preliminary results suggest that eculizumab, an anti-C5 monoclonal antibody, can also prevent relapse in NMO, Meanwhile, interferon-beta, a first-line disease modifying drug of MS, is not effective in NMO. Symptomatic therapy for pain, paresthesia, spasticity, dysuria and constipation which commonly occur in the chronic stage of NMO is also important to improve patients' quality of life.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
molihuakai的应助被杨希采纳,获得10
刚刚
1秒前
kskfjs完成签到,获得积分10
1秒前
1秒前
李煜东完成签到,获得积分10
2秒前
CodeCraft的应助被江就采纳,获得30
2秒前
KON发布了新的文献求助10
3秒前
土豆发布了新的文献求助10
3秒前
3秒前
CAOHOU的应助被树123采纳,获得10
4秒前
Yoghurt完成签到,获得积分10
4秒前
丙午完成签到,获得积分10
4秒前
木华完成签到,获得积分10
5秒前
zzzzzzzz完成签到,获得积分10
7秒前
7秒前
7秒前
yangqisen完成签到 ,获得积分10
8秒前
大模型的应助被畅销款采纳,获得10
9秒前
Parker发布了新的文献求助10
10秒前
10秒前
11秒前
林夕发布了新的文献求助10
11秒前
juntang发布了新的文献求助10
11秒前
wwwf完成签到 ,获得积分10
11秒前
11秒前
zz完成签到,获得积分10
11秒前
12秒前
马浩然发布了新的文献求助20
14秒前
开放的丹南完成签到,获得积分10
14秒前
落后怜阳完成签到,获得积分10
16秒前
aki完成签到,获得积分10
18秒前
小蘑菇的应助被RUN20260921采纳,获得10
18秒前
xiaoy完成签到,获得积分10
19秒前
20秒前
周粤川完成签到 ,获得积分10
21秒前
inRe完成签到,获得积分10
22秒前
无花果的应助被lkx采纳,获得10
23秒前
24秒前
24秒前
畅销款发布了新的文献求助10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643